Analysts at StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
Shares of NASDAQ:APVO opened at $0.71 on Thursday. Aptevo Therapeutics has a 52 week low of $0.70 and a 52 week high of $91.96. The company’s fifty day moving average is $4.90 and its 200-day moving average is $7.90.
Institutional Investors Weigh In On Aptevo Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of Aptevo Therapeutics in the 4th quarter valued at $47,000. Sabby Management LLC acquired a new position in Aptevo Therapeutics during the 3rd quarter worth about $440,000. Armistice Capital LLC acquired a new position in Aptevo Therapeutics during the 3rd quarter worth about $408,000. Cantor Fitzgerald L. P. lifted its position in Aptevo Therapeutics by 14.8% during the 2nd quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock worth $367,000 after buying an additional 32,422 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Aptevo Therapeutics by 45.8% during the 2nd quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock worth $117,000 after buying an additional 25,200 shares in the last quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- United Airlines Soars on Earnings Beat
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Health Care Stocks Explained: Why You Might Want to Invest
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
